Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Verrica Pharmaceuticals (Nasdaq: VRCA), a company focused on developing dermatology therapeutics, announced that its President and CEO, Ted White, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City.
The event will take place on June 6, 2024, at 3:30 pm ET. A live webcast of the event will be available through the investors' section of the Verrica website, with a replay accessible for 90 days post-event.
- Verrica Pharmaceuticals' participation in a major healthcare conference enhances visibility among investors and industry stakeholders.
- Availability of a live webcast and replay increases accessibility and transparency for investors.
- The press release lacks any direct financial or clinical updates which could provide substantial information for investors to assess the company's performance.
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City.
Jefferies Global Healthcare Conference, New York, June 6, 2024.
Event details:
Date: Thursday, June 6, 2024
Time: 3:30 pm ET
Location: New York, NY
Participants may access a live webcast of the event by clicking the link here.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. VP-102 is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
Terry Kohler
Chief Financial Officer
tkohler@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
FAQ
What is the date and time of Verrica Pharmaceuticals' participation in the Jefferies Global Healthcare Conference?
How can investors access the live webcast of Verrica Pharmaceuticals' presentation at the Jefferies Global Healthcare Conference?
Will there be a replay available for Verrica Pharmaceuticals' presentation at the Jefferies Global Healthcare Conference?
